Home › Compare › NICXF vs EQR

NICXF vs EQR: Dividend Comparison 2026

NICXF yields 666.67% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NICXF wins by $608115.61M in total portfolio value
10 years
NICXF
NICXF
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full NICXF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — NICXF vs EQR

📍 NICXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNICXFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NICXF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NICXF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NICXF
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, NICXF beats the other by $399,126,861,339.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NICXF + EQR for your $10,000?

NICXF: 50%EQR: 50%
100% EQR50/50100% NICXF
Portfolio after 10yr
$304057.85M
Annual income
$234,780,512,145.92/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

NICXF
No analyst data
Altman Z
-14.8
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NICXF buys
0
EQR buys
0
No recent congressional trades found for NICXF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNICXFEQR
Forward yield666.67% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$608115.66M ✓$47.8K
Annual income after 10y$469,561,018,816.25 ✓$5,475.61
Total dividends collected$596792.85M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: NICXF vs EQR ($10,000, DRIP)

YearNICXF PortfolioNICXF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$77,367$66,666.67$11,380$679.82+$66.0K → NICXF
2$564,818$482,035.31$13,014$837.25+$551.8K → NICXF
3$3,893,246$3,288,890.67$14,961$1,036.20+$3.88M → NICXF
4$25,352,760$21,186,987.16$17,297$1,289.22+$25.34M → NICXF
5$156,070,781$128,943,327.59$20,121$1,613.15+$156.05M → NICXF
6$908,837,800$741,842,064.29$23,561$2,030.84+$908.81M → NICXF
7$5,009,769,782$4,037,313,336.56$27,783$2,573.54+$5009.74M → NICXF
8$26,159,339,258$20,798,885,591.56$33,013$3,284.39+$26159.31M → NICXF
9$129,490,317,125$101,499,824,118.87$39,547$4,223.51+$129490.28M → NICXF
10$608,115,658,140$469,561,018,816.25$47,791$5,475.61+$608115.61M → NICXF

NICXF vs EQR: Complete Analysis 2026

NICXF — Stock

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.

Full NICXF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this NICXF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NICXF vs SCHDNICXF vs JEPINICXF vs ONICXF vs KONICXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.